CANCER EPIDEMIOLOGY PROGRAM The Cancer Epidemiology program studies environmental, genetic, and molecular risks for cancer and cancer outcomes to identify priorities for public health and clinical intervention. The program has three aims: (1) Risk- Based Prevention and Early Detection: To identify opportunities for risk-based prevention and early detection of cancer; (2) Treatment, Outcomes and Survivorship: To improve cancer treatment, outcomes, and survivorship through epidemiologic and clinical research that leads to evidence-based interventions; (3) Integrative Molecular Epidemiology: To deepen understanding of cancer etiology, heterogeneity, and survivorship through integrative human molecular and histopathologic studies of precursor lesions and tumors. A major cross-cutting theme is addressing the epidemiology of health disparities. As a comprehensive cancer center in an economically, socially, and racially diverse state, CE is well-poised to address health equity. Across these aims, we use multidimensional North Carolina studies and conduct cross-program research to yield high impact findings. Members have expertise in population-based epidemiology, data linkage, pharmacoepidemiology, survey research, clinical research, screening, molecular and biomarker research, translational preclinical research, sociology, pathology, genomics, data science, computer science, and statistical and epidemiologic methods. Research resources include population-based studies of breast, colon, prostate, head and neck cancer as well as registries for breast and lung screening. Many of these studies participate in large national and international data-sharing initiatives and consortia. The Program brings value to the Center through study resources that collect exposure and outcome data, and biospecimens, a unique shared resource (Statewide Cancer Data), and expertise in epidemiologic methods. The Program is supported by UNC Lineberger?s investments in faculty recruitments, shared resources and developmental funds. The UNC Lineberger strategic plan emphasis on optimizing cancer outcomes in North Carolina has led to significant investment across population sciences and is expanding in new areas in coming years including endometrium and bladder, with sustained support for ongoing data collection in breast cancer and head and neck cancers. The CE Program consists of 33 members who are associated with 9 departments at UNC- Chapel Hill and affiliated institutions. During the last funding period, program members have published 776 cancer-related articles, 24% were inter-programmatic and 19% were intra-programmatic (34% collaborative). In 2019, our program members held grants totaling $10.0M (direct cost) in cancer-relevant extramural funding, including $5.2M (direct costs) from the NCI and $3.0M other peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089819
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Ho, G-T; Aird, R E; Liu, B et al. (2018) MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 11:120-130
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319

Showing the most recent 10 out of 1525 publications